Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.
PPAR-gamma ligands are being used for the treatment of human metabolic disorders; they also exert anti-inflammatory and antineoplastic properties that are now being explored in clinical studies. Recent data have further extended the crucial role of PPAR-gamma and its ligands in bone turnover. This review summarises the latest knowledge of the expression of PPAR-gamma in bone tissue and the regulatory effect of diverse synthetic and natural PPAR-gamma ligands on bone formation and resorption. Taking into account the data so far, PPAR-gamma ligands seem to be able to contribute to the treatment of various bone disorders including osteoporosis, as well as diabetic and age-related osteopoenia.
Giaginis
Costas
C
University of Athens, Department of Forensic Medicine and Toxicology, Medical School, 75 Mikras Asias Street, Athens 11527, Greece. theocharis@ath.forthnet.gr
Tsantili-Kakoulidou
Anna
A
Theocharis
Stamatios
S
D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy / Q000378:metabolism; D016723:Bone Remodeling / Q000187:drug effects* / Q000502:physiology; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D047495:PPAR gamma / Q000096:biosynthesis / Q000378:metabolism*
D015507:Drugs, Investigational; D008024:Ligands; D047495:PPAR gamma